Wockhardt Ltd

Past performance
Performance overview
Wockhardt Ltd
About Wockhardt Ltd Wockhardt Limited is a global pharmaceutical and biotechnology company based in India, recognized for its research-driven approach in pharmaceuticals, biotechnology, and super speciality hospitals. The company operates through 12 manufacturing sites and three R&D centers across India, the USA, the UK, and Ireland. A significant 83% of its revenue is derived from international markets, with a strong presence in the USA, Europe, and India. Notably, Wockhardt is the only company globally to receive the USFDA's Qualified Infectious Diseases Programme (QIDP) status for five anti-bacterial programs targeting 'superbugs'. The company has made strategic acquisitions and partnerships worldwide, enhancing its portfolio with groundbreaking products such as human recombinant insulin and novel antibiotics. Despite some regulatory challenges, Wockhardt continues to innovate, having filed over 3,200 patents and received 803 grants as of March 2022. With a strong focus on antibiotics, the company launched EMROK and EMROK O in India, addressing severe bacterial infections. Recent agreements with the UK Government for COVID-19 vaccine production and collaborations in China further bolster its global footprint.
Website wockhardt.com
Founded 1999
Headquarters Aurangabad.